LAURA ROSEKRANS: Open Payments
NPI 1790391936 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$394 in 21 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $274 · 2025 $394
Food & beverage: $394
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| ABBVIE INC. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| PFIZER INC. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
Products named: CAPLYTA, Kerendia, REXULTI, FANAPT, UBRELVY, Auvelity, TRELEGY ELLIPTA, NURTEC ODT.
Industry payments across MI — which companies pay providers there.
